Also, Glibencamide’s EC50 for PPARγ activation is three orders of magnitude higher than the dose received by our rAION animals.[23] Thus, neither glibenclamide-induced hypoglycemia nor PPARγ activation were considered to be factors in interpreting our results. The gene discussed is PPARG; the disease is Hypoglycemia.